NCT00070941View on ClinicalTrials.gov

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

June 30, 2010

Study Completion Date

October 31, 2010

Conditions
Parkinson's DiseaseDepression
Interventions
DRUG

SAM-e

oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.

DRUG

oral escitalopram

20mg or 30mg daily in two divided doses, along with placebo SAM-e.

DRUG

placebo

oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.

Trial Locations (1)

10003

New York University, New York

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

Office of Dietary Supplements (ODS)

NIH

lead

NYU Langone Health

OTHER

NCT00070941 - SAM-e for the Treatment of Depression in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter